Sexual HealthStrong Evidence

Bremelanotide

Also known as: PT-141, Vyleesi

Melanocortin receptor agonist, FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 is its research name.

Evidence

Strong

FDA status

FDA-approved

Source

Synthetic melanocortin receptor agonist (PT-141 is the research name)

Overview

Melanocortin receptor agonist, FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 is its research name.

Mechanism of Action

Activates MC3R and MC4R melanocortin receptors in hypothalamus and spinal cord, increases sexual desire via central dopaminergic pathways, works independently of vascular mechanisms, modulates sexual arousal centers in brain.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Increases sexual desire and arousal
  • Works centrally (brain-based)
  • Studied in men (not an approved use)
  • Independent of vascular function
  • Used as needed before sexual activity
  • Dependence (not reported in trials)

Researched for

Includes FDA-approved uses where marked; other items are research topics, not approved uses.

Acquired, generalized HSDD in premenopausal women (FDA-approved use)Low libido (off-label)Erectile dysfunction (off-label)Sexual dysfunction from SSRIsArousal disorders

How Gabriel approaches peptides

Bremelanotide can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.

Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Strong
Studies

Phase 3 RCTs, FDA approved for female HSDD

Summary

FDA-approved in 2019 based on the RECONNECT trials, which showed improved sexual desire and less distress in premenopausal women. Use in men or postmenopausal women is not approved.

Safety Information

Potential Side Effects

  • •Nausea (common)
  • •Flushing
  • •Headache
  • •Transient hypertension
  • •Injection site reactions

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy
  • Breastfeeding

Interactions

  • ⚠Caution with antihypertensives
  • ⚠Can lower absorption of naltrexone taken by mouth

Quick Facts

CategorySexual Health
SourceSynthetic melanocortin receptor agonist (PT-141 is the research name)
StatusFDA-approved (Vyleesi) for HSDD in premenopausal women